adrenergic receptor Agonists
2 drugsAbout adrenergic receptor
Adrenergic receptors are a family of GPCRs activated by catecholamines like norepinephrine and epinephrine, regulating physiological processes. They are significant drug targets due to their involvement in various pathways.
While there is currently no genetic evidence directly linking adrenergic receptors to specific diseases, their role in diverse pathways makes them relevant across multiple therapeutic areas.
Two FDA-approved small molecule drugs, CLOZAPINE and VERSACLOZ, target adrenergic receptors, primarily for CNS indications. These drugs from Teva and Douglas highlight continued interest in adrenergic receptors.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Treatment-resistant Schizophrenia with only 1 trials.
Top adrenergic receptor Drugs
The competitive landscape includes two companies, Teva and Douglas Pharmaceuticals, with approved drugs.
Low market concentration suggests relatively low barriers to entry, but also potentially lower profitability.
adrenergic receptor Drug Modality Landscape
Modalities
Routes of Administration
adrenergic receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore opportunities to develop novel modalities like antibodies or biologics to differentiate from existing therapies.
adrenergic receptor Clinical Trials 24 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 3 | 3 | 1 | 1 | 1 | 50% |
| Phase 4 | 19 | 11 | 2 | 6 | 85% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
adrenergic receptor Drug Approval Timeline (1996 - 2013)
The first drug was approved in 1996 (CLOZAPINE), and the most recent in 2013 (VERSACLOZ), spanning 18 years.
The approval timeline shows a slowing pace, indicating potential saturation or increased regulatory hurdles.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 28 clinical trials targeting adrenergic receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities